36
Participants
Start Date
March 31, 2022
Primary Completion Date
February 24, 2025
Study Completion Date
February 24, 2026
Cyclophosphamide
Given IV
Neoantigen Peptide Vaccine
Receive personalized neoantigen vaccine SC
Pembrolizumab
Given IV
Sargramostim
Given SC
RECRUITING
Mayo Clinic in Florida, Jacksonville
Lead Sponsor
Mayo Clinic
OTHER